Rory Budihandojo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rory Budihandojo


Rory Budihandojo
Director, Quality Systems Audit
Boehringer Ingelheim Shanghai Pharmaceuticals

Rory Budihandojo is the director of quality systems audit at Boehringer Ingelheim Shanghai Pharmaceuticals. He has more than 20 years of worldwide pharmaceutical experience (including Pfizer, GSK, Schering Plough) with responsibilities in R&D, manufacturing (API and finished dosage), QA, IT, pharmaceutical technology, and quality audit. He performed method, process, facility, utility, equipment, and computer validation, as well as GMP auditing of contract manufacturers, suppliers, and internal audits. He has validated chromatography, LIMS, PLC, SCADA, DCS, DMS, BAS, ERP, SAP, change-control systems, and more. 

He was a member of PhRMA and PDA CSV Committee, and a founding member of GAMP Americas, and now serves as the vice-chairman and as a global GAMP Council member. He has published several articles in computer validation and was the lead author of PDA Technical Report No. 31. He serves on the editorial board of Pharmaceutical Technology, BioPharm International, Pharma Magazine, Pharm Tech Europe, and Pharmaceutical Engineering. He has a diploma in electronics, and degrees in chemistry and mathematics.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here